JP2001513370A5 - - Google Patents

Download PDF

Info

Publication number
JP2001513370A5
JP2001513370A5 JP2000507005A JP2000507005A JP2001513370A5 JP 2001513370 A5 JP2001513370 A5 JP 2001513370A5 JP 2000507005 A JP2000507005 A JP 2000507005A JP 2000507005 A JP2000507005 A JP 2000507005A JP 2001513370 A5 JP2001513370 A5 JP 2001513370A5
Authority
JP
Japan
Prior art keywords
vitamin
dialysis solution
pharmaceutically acceptable
acceptable salt
carnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000507005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001513370A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/016383 external-priority patent/WO1999007419A1/en
Publication of JP2001513370A publication Critical patent/JP2001513370A/ja
Publication of JP2001513370A5 publication Critical patent/JP2001513370A5/ja
Pending legal-status Critical Current

Links

JP2000507005A 1997-08-07 1998-08-06 水溶性ビタミン及び栄養素を含む透析溶液 Pending JP2001513370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5501597P 1997-08-07 1997-08-07
US60/055,015 1997-08-07
PCT/US1998/016383 WO1999007419A1 (en) 1997-08-07 1998-08-06 Dialysis solutions containing water soluble vitamins and nutrients

Publications (2)

Publication Number Publication Date
JP2001513370A JP2001513370A (ja) 2001-09-04
JP2001513370A5 true JP2001513370A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=21995013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507005A Pending JP2001513370A (ja) 1997-08-07 1998-08-06 水溶性ビタミン及び栄養素を含む透析溶液

Country Status (6)

Country Link
US (1) US6537976B1 (cg-RX-API-DMAC10.html)
EP (1) EP1009452A4 (cg-RX-API-DMAC10.html)
JP (1) JP2001513370A (cg-RX-API-DMAC10.html)
AU (1) AU8898898A (cg-RX-API-DMAC10.html)
CA (1) CA2299346A1 (cg-RX-API-DMAC10.html)
WO (1) WO1999007419A1 (cg-RX-API-DMAC10.html)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436969B1 (en) 1995-09-12 2002-08-20 Kansas University Medical Center Research Institute Inc. Dialysis solutions and methods
JPH1171273A (ja) * 1997-08-29 1999-03-16 Terumo Corp 腹膜透析液
JP3382159B2 (ja) * 1998-08-05 2003-03-04 株式会社東芝 情報記録媒体とその再生方法及び記録方法
US7670491B2 (en) 1998-10-20 2010-03-02 Advanced Renal Technologies Buffered compositions for dialysis
CA2360311C (en) * 1999-04-06 2003-03-18 Raja Khalifah Improved dialysis solutions and methods
US7186420B2 (en) * 1999-04-26 2007-03-06 Edwards Lifesciences Corporation Multi-part substitution infusion fluids and matching anticoagulants
WO2001021233A1 (en) 1999-09-22 2001-03-29 Advanced Renal Technologies High citrate dialysate and uses thereof
MXPA02003635A (es) 1999-10-11 2002-10-23 Sigma Tau Ind Farmaceuti Uso de l-carnitina y sus derivados de alcanoilo como agentes osmoticos en soluciones para uso medico.
US6914076B2 (en) 2000-01-19 2005-07-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treating chronic uremic patients undergoing periodical dialysis
CA2381187C (en) * 2000-01-19 2009-06-02 Claudio Cavazza Intravenous carnitine for the treatment of chronic uraemic patients undergoing periodical dialysis
US6429230B1 (en) * 2000-01-19 2002-08-06 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Treating chronic uremic patients undergoing periodical dialysis
US7696219B2 (en) * 2000-09-27 2010-04-13 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiences in renal patients
US6995166B1 (en) 2000-09-27 2006-02-07 Everett Laboratories, Inc. Method and composition for supplementation of nutritional deficiencies in renal patients
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US6994706B2 (en) 2001-08-13 2006-02-07 Minnesota Medical Physics, Llc Apparatus and method for treatment of benign prostatic hyperplasia
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US6814983B2 (en) 2002-12-10 2004-11-09 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
AU2004287440A1 (en) * 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
RU2006118801A (ru) * 2003-10-31 2007-12-10 Алза Корпорейшн (Us) Композиции и лекарственные формы для усиления всасывания габапентина и прегабалина
US8187467B2 (en) * 2003-12-30 2012-05-29 Ajay Gupta Parenteral administration of pyrophosphate for prevention or treatment of phosphate or pyrophosphate depletion
US8101587B2 (en) 2004-08-12 2012-01-24 Everett Laboratories, Inc. Kits for nutrition supplementation
JP2006075195A (ja) * 2004-09-07 2006-03-23 Jms Co Ltd Lカルニチン含有腹膜透析液
US7235589B2 (en) * 2004-09-21 2007-06-26 Bio Numerik Pharmaceuticals, Inc. Method of treating patients undergoing kidney dialysis
TWI388318B (zh) * 2005-03-10 2013-03-11 西格瑪 陶製藥廠 具有改良之生物相容性的含有肉毒鹼之腹膜透析溶液
CN101227904A (zh) * 2005-05-24 2008-07-23 学校法人东海大学 腹膜保护剂
JP2007056013A (ja) * 2005-07-29 2007-03-08 Ajinomoto Co Inc 透析用補充液
ES2634142T3 (es) * 2005-12-23 2017-09-26 Ajay Gupta Composición de nutrición parenteral que contiene hierro
JP4224117B1 (ja) * 2007-08-15 2009-02-12 株式会社ケイロン・ジャパン 腹膜透析液
US7658952B2 (en) 2007-10-11 2010-02-09 Baxter International Inc. Dialysis solutions containing pyrophosphates
US10117707B2 (en) 2008-04-29 2018-11-06 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US9198733B2 (en) 2008-04-29 2015-12-01 Virginia Tech Intellectual Properties, Inc. Treatment planning for electroporation-based therapies
US10448989B2 (en) 2009-04-09 2019-10-22 Virginia Tech Intellectual Properties, Inc. High-frequency electroporation for cancer therapy
US10238447B2 (en) 2008-04-29 2019-03-26 Virginia Tech Intellectual Properties, Inc. System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress
EP2280741A4 (en) 2008-04-29 2012-06-13 Virginia Tech Intell Prop IRREVERSIBLE ELECTROPORATION FOR THE PRODUCTION OF TISSUE OBJECTS
US11254926B2 (en) 2008-04-29 2022-02-22 Virginia Tech Intellectual Properties, Inc. Devices and methods for high frequency electroporation
US11272979B2 (en) 2008-04-29 2022-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies
US9867652B2 (en) 2008-04-29 2018-01-16 Virginia Tech Intellectual Properties, Inc. Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
US10702326B2 (en) 2011-07-15 2020-07-07 Virginia Tech Intellectual Properties, Inc. Device and method for electroporation based treatment of stenosis of a tubular body part
US12697172B2 (en) 2008-04-29 2026-08-04 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US10272178B2 (en) 2008-04-29 2019-04-30 Virginia Tech Intellectual Properties Inc. Methods for blood-brain barrier disruption using electrical energy
US8992517B2 (en) 2008-04-29 2015-03-31 Virginia Tech Intellectual Properties Inc. Irreversible electroporation to treat aberrant cell masses
US10245098B2 (en) 2008-04-29 2019-04-02 Virginia Tech Intellectual Properties, Inc. Acute blood-brain barrier disruption using electrical energy based therapy
US9283051B2 (en) 2008-04-29 2016-03-15 Virginia Tech Intellectual Properties, Inc. System and method for estimating a treatment volume for administering electrical-energy based therapies
US8632534B2 (en) 2009-04-03 2014-01-21 Angiodynamics, Inc. Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD)
US11638603B2 (en) 2009-04-09 2023-05-02 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US11382681B2 (en) 2009-04-09 2022-07-12 Virginia Tech Intellectual Properties, Inc. Device and methods for delivery of high frequency electrical pulses for non-thermal ablation
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
US8425455B2 (en) 2010-03-30 2013-04-23 Angiodynamics, Inc. Bronchial catheter and method of use
WO2012029655A1 (ja) * 2010-08-30 2012-03-08 国立大学法人東北大学 血液透析痙攣抑制剤
WO2012051433A2 (en) 2010-10-13 2012-04-19 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
DE102011008185A1 (de) 2011-01-10 2012-07-12 Fresenius Medical Care Deutschland Gmbh Herstellung von Individualkonzentrat
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
JP6049685B2 (ja) 2011-03-23 2016-12-21 ネクステージ メディカル インコーポレイテッド 腹膜透析使い捨てユニット、コントローラ、腹膜透析システム
US9078665B2 (en) 2011-09-28 2015-07-14 Angiodynamics, Inc. Multiple treatment zone ablation probe
US9414881B2 (en) 2012-02-08 2016-08-16 Angiodynamics, Inc. System and method for increasing a target zone for electrical ablation
DE102012002497A1 (de) 2012-02-10 2013-08-14 Fresenius Medical Care Deutschland Gmbh Verbinder mit einem Behälter zur Herstellung einer individuell angepassten Lösung für die Dialyse
US9888956B2 (en) 2013-01-22 2018-02-13 Angiodynamics, Inc. Integrated pump and generator device and method of use
KR102236226B1 (ko) * 2013-05-08 2021-04-02 감브로 룬디아 아베 투석 제제
EP3143124B1 (en) 2014-05-12 2025-01-22 Virginia Tech Intellectual Properties, Inc. Selective modulation of intracellular effects of cells using pulsed electric fields
US12114911B2 (en) 2014-08-28 2024-10-15 Angiodynamics, Inc. System and method for ablating a tissue site by electroporation with real-time pulse monitoring
WO2016100325A1 (en) 2014-12-15 2016-06-23 Virginia Tech Intellectual Properties, Inc. Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment
DE102015007842A1 (de) * 2015-06-18 2016-12-22 Fresenius Medical Care Deutschland Gmbh Dialyselösung
WO2018039297A1 (en) 2016-08-26 2018-03-01 Dabdoub Atif Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
SE542106C2 (en) 2016-08-26 2020-02-25 Atif M Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
GR1009311B (el) * 2017-01-26 2018-06-19 Βερμα Ντραγκς - Verma Drugs Abee Οξινο κιτρικο διαλυμα αιμοκαθαρσης με l-καρνιτινη
WO2018237375A1 (en) 2017-06-24 2018-12-27 Nxstage Medical, Inc. Peritoneal dialysis fluid preparation and/or treatment devices methods and systems
US11607537B2 (en) 2017-12-05 2023-03-21 Virginia Tech Intellectual Properties, Inc. Method for treating neurological disorders, including tumors, with electroporation
CA3092575A1 (en) 2018-02-28 2019-09-06 Nxstage Medical, Inc. Fluid preparation and treatment devices, methods, and systems
US12390262B2 (en) 2018-03-13 2025-08-19 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11311329B2 (en) 2018-03-13 2022-04-26 Virginia Tech Intellectual Properties, Inc. Treatment planning for immunotherapy based treatments using non-thermal ablation techniques
US11925405B2 (en) 2018-03-13 2024-03-12 Virginia Tech Intellectual Properties, Inc. Treatment planning system for immunotherapy enhancement via non-thermal ablation
US11950835B2 (en) 2019-06-28 2024-04-09 Virginia Tech Intellectual Properties, Inc. Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy
US12214189B2 (en) 2019-07-24 2025-02-04 Virginia Tech Intellectual Properties, Inc. Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies
GR1010190B (el) * 2020-11-24 2022-03-17 Βερμα Ντραγκς - Verma Drugs Abee, Οξινο κιτρικο διαλυμα αιμοκαθαρσης με l-ασκορβικο οξυ (βιταμινη c)
US12485279B2 (en) 2020-11-25 2025-12-02 Virginia Tech Intellectual Properties, Inc. Methods for modulating temporal infrastructure of pulsed electric fields
DE102023132532A1 (de) 2023-11-22 2025-05-22 B.Braun Avitum Ag Flüssige Zubereitung und Kit zur extrakorporalen Blutbehandlung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4756838A (en) * 1980-02-21 1988-07-12 Veltman Preston Leonard Preparation of dry dialysate products
US5563126A (en) * 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
DE3821043A1 (de) * 1988-06-22 1989-12-28 Fresenius Ag Dialysier- und spuel-loesung zur intraperitonealen verabreichung
US5230996A (en) 1990-06-04 1993-07-27 Therapy 2000 Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
DK0555087T3 (da) 1992-02-04 1999-05-03 Baxter Int Peritoneale dialyseopløsninger indeholdende mindst ét dipeptid
AU4792993A (en) * 1992-07-30 1994-03-03 Andrew Stone Dialysis system, method and filtrate solution composition
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5635199A (en) * 1995-10-27 1997-06-03 Nestec Ltd. Support of pediatric patients
US5851985A (en) * 1996-08-16 1998-12-22 Tepic; Slobodan Treatment of tumors by arginine deprivation

Similar Documents

Publication Publication Date Title
WO2004110346A3 (en) Sustained release of antiinfectives
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
CA2336376A1 (en) Microparticle formulation for inhalation
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
IL156102A0 (en) Hemodiafiltation/hemofiltration cartridges
JP2003513039A5 (cg-RX-API-DMAC10.html)
WO2002074238A3 (en) Water soluble and palatable complexes
BG105459A (en) Pharmaceutical moxifloxacin preparation
JP2003506416A5 (cg-RX-API-DMAC10.html)
CA2343123A1 (en) Active substance concentrate with formoterol, suitable for storage
EP0787497A3 (en) Pharmaceutical preparation containing human growth hormone
WO2003051275A3 (en) Benzodiazepine derivatives, preparation thereof and use thereof
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
PL354414A1 (en) Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use
EP1440689A3 (en) Treatment of neurotic disorders
HU9301672D0 (en) Method for manufacturing solid dosing forms of medicaments with controlled releasing of active agents
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
BR9713653B1 (pt) composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço farmacÊutica, e, uso de pirofosfato fÉrrico.
JP2002537232A5 (cg-RX-API-DMAC10.html)
JP2002515439A5 (cg-RX-API-DMAC10.html)
WO2003094905A8 (en) Diclofenac-based composition for the topical treatment of oropharyngeal cavity disorders
EE04264B1 (et) Naatriumkloriidi kasutamine aine valmistamiseks kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsete kõrvaltoimete vähendamiseks
WO2001093853A8 (en) Management of snoring by oral administration of dimethyl sulfone